Applied technology that drives scientific discovery benevolent.ai harnesses artificial intelligence to enhance and accelerate scientific discovery by making sense of highly fragmented information to create new insights and usable knowledge that benefit society. Our Story
Joining the dots in a highly fragmented world of information Despite the huge growth of knowledge and information (a new paper is published every 30 seconds), the process of scientific discovery has not changed for 50 years. Consequently, only a small fraction of globally generated scientific information has been used to form usable knowledge. benevolent.ai is solving this problem by harnessing the power of artificial intelligence to enable the analysis of vast amounts of scientific information. By doing so, it is giving the brightest scientific minds the augmented insight and analytical tools they need to create usable and deep knowledge – allowing the rapid acceleration of scientific discovery.
Applying AI to benefit mankind benevolent.ai is a technology company which is developing and applying advanced technologies to solve some of the biggest challenges facing mankind. Our proprietary artificial intelligence and machine learning technology together with benevolent.ai’s unique team of the world’s best scientists and technologists enables the Company to access and analyse huge amounts of scientific data, test hypotheses and draw conclusions faster By harnessing its technology, the company has already accelerated major breakthroughs in the area of human health – particularly in the study of neurological diseases
Creating usable knowledge for new drug discovery Nowhere do humans create more complex data and information than in pharmaceutical R&D. Until now, we haven’t had the means to connect, analyse and use this mass of information effectively. In forging a union between biomedicine and artificial technology, benevolent.ai has discovered the key to accelerating major new discoveries in the pharmaceutical sector. The application of its technology has the potential to minimise the huge costs, time scales and risks associated with the development of new drugs. Currently the company is focussed on discovering breakthrough treatments for neurological diseases such as Parkinson’s and Alzheimer’s disease, orphan diseases such as Amyotrophic Lateral Sclerosis (ALS) and rare cancers.
Sep 16, 2016 events Artificial Intelligence in Bioscience Hosted by: benevolent.ai Venue: The Royal Society, 6-9 Carlton House Terrace, London SW1Y 5AG View all events
Sep 9, 2016 news Benevolent.ai Appoints Artificial Intelligence Industry Pioneer as CEO of Benevolent Technology View all news
Aug 31, 2016 news Leading British Technology Company Rebrands to Better Reflect Power and Breadth of Technology View all news
benevolent.ai bio If battling diseases is your thing, come and join the team to help deliver the next big drug discovery View jobs
benevolent.ai tech Come join the team and help us develop the next major breakthrough in applied AI technology View jobs